Clinical trials: Immune Resistance
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, HIV/AIDS
Diabetes Mellitus and HIV Study in Mwanza
Emerging evidence from high-income countries suggests that diabetes mellitus is become a major health problem among HIV-infected patients.
- Trial name
- CICADA (NCT03106480)
- Where
- Tanzania
- Volunteers
- 1,947 people
- Sponsor
- National Institute for Medical Research, Tanzania
Thyroid Eye Disease, TED, Graves Ophthalmopathy
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease (TED), also known as Graves' orbitopathy, is an autoimmune condition that causes inflammation and tissue expansion behind the eyes, leading to bulging eyes (proptosis), double vision, and pain.
- Conditions
- Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
- Trial name
- TOFA-GO (NCT07547930)
- Testing
- Tofacitinib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Multiple Sclerosis
Effects of Resistance Training in Multiple Sclerosis: a Randomized Trial.
This is a longitudinal study to examine the effects of a short-term training program on neurofilamet and GFAP plasma levels. Participants will be divided in two groups: control group (moderate aerobic training) and active group…
- Trial name
- ACTIVE (NCT06478784)
- Testing
- Resistance training, Low aerobic training
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Diabetes Type 1
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes.
- Trial name
- SEMPA (NCT06894784)
- Testing
- Intervention Period 1: Semaglutide + Empagliflozin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV Infections
Use of a Test That Evaluates How the Body Handles Insulin and Glucose
The purpose of this study is to find out if testosterone gel affects how the body handles insulin and glucose. Specific anti-HIV treatments may increase a patient's risk of certain diseases by causing metabolic problems such as…
- Trial name
- NCT00027092
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes Mellitus
Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections
The purpose of this study is to evaluate that Finesse, for prandial insulin bolusing when used in conjunction with basal insulin, achieves equivalent glycemic control when compared to multiple daily injections and to evaluate its…
- Trial name
- NCT01073566
- Testing
- Finesse, Pen/Syringe (Usual injection device)
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Calibra Medical, Inc.
HIV Infections
A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body
The purpose of this study is to find out if anti-HIV drugs can be stopped without the virus becoming resistant to the drugs. The study will also examine how fast anti-HIV drugs leave the body.
- Trial name
- NCT00029341
- Testing
- Treatment Interruption
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Metastatic Malignant Neoplasm
Cryoablation for the Treatment of Metastatic Cancer
This interventional trial studies the effectiveness of adding cryoablation treatment in patients who are receiving standard of care immunotherapy to treat cancer that is has spread to other parts of the body (metastatic).
- Trial name
- NCT04150939
- Testing
- Core Biopsy, Cryosurgery, Immunotherapeutic Agent
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
MYeloma Resistance And Clonal Evolution
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis.
- Trial name
- MYRACLE (NCT03807128)
- Testing
- Prélèvement sanguin (2*4mL) ou médullaire (2mL), Data collection through questionnaires
- Where
- 2 sites in France
- Volunteers
- 1,400 people
- Sponsor
- Nantes University Hospital
Protein Deficiency, Training Group, Sensitivity
Effects of a Recovery Supplement on Body Composition, Performance, Muscular Properties, and Wellbeing
The investigation will be conducted as a double blinded, randomized, parallel between treatment conditions comparison design with two different groups ingesting a different supplement each one.
- Conditions
- Protein Deficiency, Training Group, Sensitivity, Fatigue, Muscular Atrophy
- Trial name
- NCT05769101
- Testing
- Ingestion of a Post-Workout Supplement, Ingestion of a Maltodextrin Supplement
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Joel Puente
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA
Metastatic Hormone-Sensitive Prostate Cance
A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics
This study will follow patients with metastatic hormone-sensitive prostate cancer (mHSPC) who receive androgen deprivation therapy (ADT) combined with different treatments.
- Trial name
- NCT07154914
- Testing
- Abiraterone + ADT
- Volunteers
- 396 people
- Sponsor
- Anhui Medical University
Type 1 Diabetes, Insulin Sensitivity/Resistance
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
GLP-1 increases skeletal and cardiac microvascular perfusion and improves insulin's microvascular responses in human subjects with T1DM, leading to improved metabolic insulin responses, endothelial function, and increased muscle…
- Trial name
- KML001 (NCT04133922)
- Testing
- GLP-1, Insulin, Dextrose 20 % in Water
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Virginia
Lymphoma, B-Cell, Lymphoma, Hodgkin
STAY-STRONG Study of Exercise Training During Chemotherapy
This study evaluates the effectiveness of a supervised progressive resistance training program in patients malignant lymphomas with the primary outcome being lean body mass.
- Conditions
- Lymphoma, B-Cell, Lymphoma, Hodgkin, Exercise, Body Composition
- Trial name
- STAY-STRONG (NCT05556239)
- Testing
- Resistance Exercise Training
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00227695
- Testing
- rituximab
- Where
- 26 sites in Brazil, Italy and 5 more
- Volunteers
- 270 people
- Sponsor
- Swiss Cancer Institute
Candidemia of C. Glabrata
Study of Innate Host Immune Response to C. Glabrata Clinical Isolates Resistant to Echinocandins: Impact on the Management of Candidemia in High-risk Patients
In the context of Candida yeast infections, a large number of studies have been published over the past two decades specifying the molecular mechanisms of antifungal resistance in different Candida species.
- Trial name
- CAHOHR (NCT03652194)
- Testing
- in vitro evaluation of epithelial immune response during C. glabrata infection, study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes Mellitus, Type 2, Autoimmune Diabetes
Metabolic and Immunoinflammatory Profiles in Adults With Newly Diagnosed Diabetes
The goal of this observational study is to better understand how diabetes develops in adults at the time of diagnosis. The study focuses on adults with newly diagnosed diabetes in the Kazakh population.
- Trial name
- AD-HET-KZ (NCT07522502)
- Where
- Kazakhstan
- Volunteers
- 240 people
- Sponsor
- West Kazakhstan Marat Ospanov Medical University
Prostatic Neoplasms, Castration-Resistant
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the effects of 4 cycles of combinatory immunotherapy (ipilimumab and nivolumab), followed by monotherapy nivolumab in participants with immunogenic metastatic castration-resistant prostate…
- Trial name
- INSPIRE (NCT04717154)
- Testing
- Ipilimumab, Nivolumab
- Where
- Netherlands
- Volunteers
- 69 people
- Sponsor
- Radboud University Medical Center